cobicistat
cobicistat: 5 clinical trials tracked.
cobicistat evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about cobicistat, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 3 study sponsors
Clinical Trial Registry Records (5)
An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments
Primary endpoint: Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Primary endpoint: Number of Women Who Meet Area Under the Curve (AUC) Target in Plasma (Component 1)
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Primary endpoint: Number of participants with dose-limiting toxicities (DLTs) (Phase 1)
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Efficacy: Best Objective Response Rate Percent by Treatment Group
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants
Primary endpoint: Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV